Moderate Evidence
Research Overview
Oveporexton Research for Narcolepsy Type 2
An overview of research and source records on Oveporexton in the context of narcolepsy type 2.
Research Summary
NT2 patients have excessive sleepiness without cataplexy and usually normal CSF orexin. The Phase 2 trial NCT05687916 evaluated whether OX2R agonism benefits this population with less clear orexin dysfunction.
References
Open a reference to inspect its source record. A citation does not establish a clinical benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.